Seagen, Inc.
Bothell
WA
United States
719 articles with Seagen, Inc.
-
Seagen Reports Third Quarter 2020 Financial Results
10/29/2020
-Net Product Sales $267.5 Million in 3Q20, an Increase of 60 Percent Over 3Q19- -Collaborations with Merck for Ladiratuzumab Vedotin and TUKYSA; Seagen Received $725M in Upfront Payments and $1B Equity Investment- -Positive Data from Two PADCEV Clinical Trials to Support Global Registration Applications and Expand U.S. Indication- -Positive Data from Tisotumab Vedotin Pivotal Trial; BLA Planned to Support U.S. Accelerated Approval-
-
Seagen Announces Closing of $1.0 Billion Stock Sale to Merck
10/28/2020
-Merck’s Equity Stake in Seagen in Connection with Agreement to Co-Develop and Commercialize Ladiratuzumab Vedotin-
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020
10/13/2020
Seagen Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2020 financial results on Thursday, October 29, 2020 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: Thursday, October 29, 2020 1:30 p.m. Pac
-
Despite the change of corporate name, the company said it will maintain its focus on the pursuit of developing novel therapies for solid tumors and blood-related cancers.
-
Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.
10/8/2020
Seagen Inc. is the new corporate name for Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company dedicated to developing innovative cancer medicines that make a meaningful difference in people’s lives around the world. The evolution of the corporate name reflects the transformation of Seagen as it expands operations g
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
9/21/2020
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - Data Featured in Late-Breaking Proffered Paper Oral Presentation - - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - BOTHELL, Wash. & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) an
-
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
9/18/2020
Seattle Genetics, Inc. and Astellas Pharma Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.
-
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
9/18/2020
Astellas Pharma Inc. and Seattle Genetics, Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.
-
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
9/14/2020
Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock
-
Merck is making a major investment into Bothwell, Washington-based Seattle Genetics with two strategic oncology deals.
-
Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
9/3/2020
Seattle Genetics to Present at the Morgan Stanley 18 th Annual Global Healthcare Conference
-
Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)
8/27/2020
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSK’s BLENREP™ (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. In
-
Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020
8/27/2020
- Positive Tisotumab Vedotin Phase 2 innovaTV 204 Data in Recurrent or Metastatic Cervical Cancer to be Featured in Late-Breaking Oral Presentation - - Data to be Presented from 11 Additional Abstracts Covering Marketed or Clinical-Stage Programs -
-
Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
8/18/2020
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the company’s Board of Directors. Dr. Love has more than 25 years of global experience in the healthcare and biotechnology/pharmaceutical industry and currently serves as President and Chief Executive Officer of Global Blood Therapeutics. “We are pleased to welcome Ted to our Board of Directors given his distinguished
-
With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.
-
Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative
8/12/2020
Seattle Genetics Announces TUKYSA ® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative - Australia Joins U.S., Switzerland, Canada and Singapore in Approval of TUKYSA for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer -
-
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
8/6/2020
-Approval of ADC Utilizing Seattle Genetics’ Proprietary Technology Generates $20 Million Milestone Payment and Future Royalties on Worldwide Net Sales- BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline’s (GSK) BLENREP™ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle G
-
Seattle Genetics Reports Second Quarter 2020 Financial Results
7/30/2020
Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020.